Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19205510 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | May 2025 | June 2025 | Allow | 1 | 0 | 0 | Yes | No |
| 18809240 | COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS | August 2024 | March 2026 | Allow | 19 | 3 | 1 | Yes | No |
| 18795731 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795711 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795683 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18758007 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18752293 | LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF | June 2024 | January 2026 | Allow | 19 | 3 | 0 | No | No |
| 18606407 | STABLE CHLORINATED ALKALINE PRODUCTS | March 2024 | March 2026 | Allow | 24 | 1 | 0 | Yes | No |
| 18692195 | POROUS AEROGEL SCAFFOLD, METHOD OF PREPARING THE SAME AND USE THEREOF | March 2024 | August 2025 | Allow | 17 | 0 | 0 | Yes | No |
| 18444485 | Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof | February 2024 | April 2025 | Allow | 14 | 2 | 1 | No | No |
| 18443689 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | February 2024 | May 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18430003 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | February 2024 | January 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18421405 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | January 2024 | July 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18367542 | MONOGLYCEROL ACRYLATE BASED POLYMER AND USES THEREOF | December 2023 | March 2026 | Allow | 30 | 0 | 1 | Yes | No |
| 18518100 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | November 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18518093 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | November 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18518110 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | November 2023 | March 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18385915 | METHOD FOR PREPARING NANO-IMMUNE ACTIVATOR, ARTICLE AND USE THEREOF | November 2023 | February 2026 | Allow | 28 | 1 | 1 | No | No |
| 18498553 | PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS | October 2023 | January 2026 | Allow | 27 | 1 | 0 | Yes | No |
| 18558335 | LIPID COMPOUND AND USE THEREOF IN DELIVERY OF NUCLEIC ACID | October 2023 | October 2025 | Allow | 24 | 0 | 1 | No | No |
| 18490188 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18490197 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | October 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18470280 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | September 2023 | December 2024 | Allow | 14 | 2 | 1 | No | No |
| 18462956 | Taxane Analogs for the Treatment of Brain Cancer | September 2023 | February 2026 | Allow | 29 | 1 | 0 | Yes | No |
| 18448347 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | October 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18448309 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | October 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18448312 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | January 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18448333 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | September 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18229728 | ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUM | August 2023 | June 2024 | Allow | 11 | 2 | 1 | No | Yes |
| 18363641 | INSECTICIDAL TABLET COMPOSITIONS | August 2023 | December 2025 | Allow | 28 | 5 | 1 | Yes | Yes |
| 18361981 | Dendritic Macroporous Hydrogels Prepared By Crystal Templating | July 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18216890 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | June 2023 | February 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18346015 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISORDERS | June 2023 | March 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18211834 | Hygiene Product Pod and Methods of Using Same | June 2023 | January 2026 | Allow | 31 | 2 | 0 | Yes | No |
| 18144800 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | May 2023 | February 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18251929 | COMPOSITION FOR TREATING AND/OR PREVENTING FUNGAL INFECTIONS | May 2023 | December 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18032493 | NANOPARTICLES FOR USE IN ANTI PATHOGENIC APPLICATIONS | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18297698 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | April 2023 | September 2025 | Allow | 29 | 1 | 0 | No | No |
| 18187878 | Targeting Microbubbles | March 2023 | July 2025 | Allow | 28 | 1 | 0 | No | No |
| 18246151 | COMPOSITIONS COMPRISING REACTION PRODUCTS OF SACCHARIDE POLYMERS AND FATTY ESTERS FORMULATED WITH A NEUTRAL SURFACTANT | March 2023 | December 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18178789 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | March 2023 | July 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18044015 | USE, IN AQUEOUS-ALCOHOLIC COMPOSITIONS, OF A COPOLYMER OBTAINED BY PRECIPITATION POLYMERIZATION | March 2023 | March 2025 | Abandon | 24 | 3 | 0 | Yes | No |
| 18170185 | LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOF | February 2023 | January 2026 | Allow | 35 | 3 | 0 | No | No |
| 18040496 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | February 2023 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18161264 | EXTENDED RELEASE LIQUID COMPOSITIONS OF GUAIFENESIN | January 2023 | September 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18151846 | ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODS | January 2023 | November 2023 | Abandon | 10 | 1 | 0 | No | No |
| 18094050 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | January 2023 | March 2024 | Allow | 14 | 3 | 0 | Yes | No |
| 18148766 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | December 2022 | June 2023 | Allow | 5 | 1 | 0 | No | No |
| 18090582 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | December 2022 | February 2024 | Allow | 13 | 3 | 0 | Yes | No |
| 18089338 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | December 2022 | February 2024 | Allow | 14 | 3 | 0 | Yes | No |
| 18083253 | Seed Treatment Methods and Compositions | December 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18064222 | METHODS OF EFFICIENTLY TREATING VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS | December 2022 | May 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18061819 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | December 2022 | February 2026 | Allow | 38 | 3 | 0 | Yes | No |
| 17993422 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | November 2022 | November 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17998998 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | November 2022 | December 2025 | Abandon | 37 | 1 | 0 | Yes | No |
| 17998895 | PARTICLE CONTAINING LIPID NANOPARTICLES AND METHOD FOR PRODUCING SAME | November 2022 | August 2025 | Allow | 33 | 2 | 0 | Yes | No |
| 18052116 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | November 2022 | December 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 18050951 | METHOD OF MANUFACTURING ANTIFOULING COATING POLYMER USING INITIATED CHEMICAL VAPOR DEPOSITION | October 2022 | May 2025 | Allow | 31 | 2 | 0 | No | No |
| 18047964 | PROCESS FOR MESALAZINE SOLID FORMULATIONS | October 2022 | October 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 18046778 | METHOD OF PREPARING NANOPARTICLES BY HOT-MELT EXTRUSION | October 2022 | December 2024 | Allow | 26 | 2 | 0 | No | No |
| 17965633 | STABILIZING VITAMIN C TOPICAL FORMULATIONS | October 2022 | June 2025 | Allow | 32 | 4 | 1 | Yes | No |
| 17961205 | STABILIZATION OF RNA FOR EXOGENOUS RNAi AGRICULTURAL APPLICATIONS AND FORMULATIONS | October 2022 | October 2025 | Allow | 36 | 4 | 1 | Yes | No |
| 17995053 | FORMULATION | September 2022 | November 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17932453 | OPHTHALMIC FORMULATIONS OF METHOTREXATE | September 2022 | March 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17932426 | OPHTHALMIC FORMULATIONS OF METHOTREXATE | September 2022 | March 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17900953 | ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAME | September 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17816486 | VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | August 2022 | December 2024 | Allow | 29 | 1 | 0 | No | No |
| 17759568 | METHODS OF CONTROLLING OR PREVENTING PANAMA DISEASE IN BANANA PLANTS | July 2022 | January 2026 | Allow | 42 | 0 | 1 | No | No |
| 17815045 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | July 2022 | March 2026 | Abandon | 43 | 2 | 0 | No | Yes |
| 17759385 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17866939 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | July 2022 | February 2024 | Allow | 19 | 4 | 1 | Yes | No |
| 17862421 | METHOD FOR PREPARING PEI-LIPID NANOPARTICLES USED FOR DELIVERING A MRNA VACCINE AND TRANSFECTING STEM CELLS | July 2022 | October 2024 | Allow | 27 | 1 | 0 | No | No |
| 17810934 | Protection of Polyunsaturated Fatty Acids from Ruminal Degradation | July 2022 | October 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17790808 | SOLUBLE MELATONIN TRIPARTATE ADDUCT FOR THE PREVENTION AND TREATMENT OF RARE AND SEVERE EYE SIGHT-THREATENING CONDITIONS AND NEURO-OPHTHALMIC DISORDERS | July 2022 | March 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17788895 | ANTI-AGING COSMETIC COMPOSITION BASED ON RESVERATROL AND MAGNOLIA | June 2022 | December 2025 | Abandon | 42 | 2 | 0 | Yes | No |
| 17843769 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | June 2022 | December 2022 | Allow | 6 | 0 | 0 | No | No |
| 17840287 | Onychomycosis Treatment Compositions and Methods | June 2022 | December 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17838364 | HAIR CARE COMPOSITIONS COMPRISING HYDROXYLATED TRIGLYCERIDE OLIGOMERS | June 2022 | May 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17744932 | EXTENDED-RELEASE DRUG DELIVERY COMPOSITIONS | May 2022 | March 2026 | Abandon | 46 | 5 | 0 | Yes | No |
| 17743679 | METHODS OF MODULATING IMMUNE ACTIVITY | May 2022 | February 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17774922 | COMPOSITION CONTAINING LEVAMLODIPINE BESYLATE HYDRATE AND ITS PREPARATION METHOD | May 2022 | February 2026 | Allow | 45 | 2 | 0 | No | No |
| 17774845 | COMPOSITION WITH SUPERABSORBENT POLYMER | May 2022 | May 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17774229 | COMPOSITIONS AND METHODS FOR DELIVERING CANNABINOIDS TO SKIN | May 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17735820 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | May 2022 | December 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17773995 | PYRIDYLOXYACETIC ACID COMPOUND AND USE OF SAME | May 2022 | May 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17734420 | ESLICARBAZEPINE SUSPENSION | May 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17722688 | ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUM | April 2022 | April 2023 | Allow | 12 | 2 | 1 | Yes | Yes |
| 17715355 | PHOTOPROTECTIVE COMPOSITIONS COMPRISING A DIBENZOYLMETHANE DERIVATIVE, A MEROCYANINE COMPOUND AND A COMPOUND CAPABLE OF ACCEPTING THE TRIPLET EXCITED LEVEL ENERGY OF THE DIBENZOYLMETHANE COMPOUND | April 2022 | November 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17712742 | Onychomycosis Treatment Methods | April 2022 | November 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17655615 | BOWEL CLEANSING CHEMICAL COMPOSITION AND ASSOCIATED USE THEREFORE | March 2022 | July 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17692521 | SOFT GELATIN CAPSULES CONTAINING A MIXTURE OF ANALGESICS AND DECONGESTANTS, EXPECTORANTS, ANTITUSSIVES AND/OR ANTIHISTAMINES | March 2022 | May 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17753721 | OPHTHALMIC FORMULATIONS OF METHOTREXATE | March 2022 | January 2026 | Allow | 46 | 2 | 0 | No | No |
| 17686373 | SUSPENSION COMPONENT-SPECIFIC TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USE | March 2022 | April 2022 | Allow | 1 | 0 | 0 | Yes | No |
| 17686371 | LIMITED PARTICLE SIZE TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USE | March 2022 | May 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17686368 | MOXIFLOXACIN AND TRIAMCINOLONE COMPOSITIONS AND ASSOCIATED METHODS | March 2022 | April 2022 | Allow | 1 | 0 | 0 | Yes | No |
| 17673504 | BIODEGRADABLE EXTENDED RELEASE MICROSPHERE-HYDROGEL OCULAR DRUG DELIVERY SYSTEM AND METHOD | February 2022 | December 2025 | Allow | 46 | 1 | 1 | No | No |
| 17592700 | Choline Esters | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17591250 | INDANE DERIVATIVES FOR MALODOR COUNTERACTION | February 2022 | November 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17590213 | Vaginal Hydrogel | February 2022 | August 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17584997 | ANTI-AGING DRUG COMBINATION AND USE THEREOF | January 2022 | September 2024 | Allow | 32 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEY, GENEVIEVE S.
With a 9.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALLEY, GENEVIEVE S works in Art Unit 1617 and has examined 705 patent applications in our dataset. With an allowance rate of 58.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner ALLEY, GENEVIEVE S's allowance rate of 58.3% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALLEY, GENEVIEVE S receive 2.34 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ALLEY, GENEVIEVE S is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +54.0% benefit to allowance rate for applications examined by ALLEY, GENEVIEVE S. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 28.9% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 53.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 47% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 52.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.4% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.